Novo Nordisk ONWARDS 3 and 4 Trials Achieve Primary Endpoint

(PLX AI) - Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3.• Novo Nordisk trial

Related Keywords

, Novo Nordisk , Novo , Nordisk , Onwards , Trials , Chieve , Primary , Endpoints ,